| Title |
Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer
|
|---|---|
| Published in |
Cancer Chemotherapy and Pharmacology, January 2012
|
| DOI | 10.1007/s00280-011-1817-3 |
| Pubmed ID | |
| Authors |
Sandhya Girish, Manish Gupta, Bei Wang, Dan Lu, Ian E. Krop, Charles L. Vogel, Howard A. Burris III, Patricia M. LoRusso, Joo-Hee Yi, Ola Saad, Barbara Tong, Yu-Waye Chu, Scott Holden, Amita Joshi |
| Abstract |
Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate comprising trastuzumab and DM1, a microtubule polymerization inhibitor, covalently bound via a stable thioether linker. To characterize the pharmacokinetics (PK) of T-DM1 in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, data from four studies (TDM3569g, TDM4258g, TDM4374g, and TDM4688g) of single-agent T-DM1 administered at 3.6 mg/kg every 3 weeks (q3w) were assessed in aggregate. |
Mendeley readers
The data shown below were compiled from readership statistics for 243 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 1% |
| France | 1 | <1% |
| Germany | 1 | <1% |
| Japan | 1 | <1% |
| United Kingdom | 1 | <1% |
| Unknown | 236 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 60 | 25% |
| Student > Ph. D. Student | 38 | 16% |
| Student > Bachelor | 25 | 10% |
| Other | 23 | 9% |
| Student > Master | 22 | 9% |
| Other | 33 | 14% |
| Unknown | 42 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 55 | 23% |
| Medicine and Dentistry | 38 | 16% |
| Pharmacology, Toxicology and Pharmaceutical Science | 36 | 15% |
| Chemistry | 26 | 11% |
| Biochemistry, Genetics and Molecular Biology | 17 | 7% |
| Other | 23 | 9% |
| Unknown | 48 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 21. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 June 2023.
All research outputs
#1,644,040
of 23,815,455 outputs
Outputs from Cancer Chemotherapy and Pharmacology
#32
of 2,501 outputs
Outputs of similar age
#12,169
of 250,731 outputs
Outputs of similar age from Cancer Chemotherapy and Pharmacology
#2
of 19 outputs
Altmetric has tracked 23,815,455 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,501 research outputs from this source. They receive a mean Attention Score of 4.1. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 250,731 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.